Close Menu

North America

Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.

Thermo Fisher said the assay is the first and, so far, only FDA-approved test of its kind for a targeted treatment for RET fusion-positive NSCLC.

A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors. 

The collaborators said they're creating a solution for pharmaceutical clients that will encompass everything from patient recruitment to regulatory approvals.

Patients with metastatic solid tumors who are ineligible for surgical resection and who are out of treatment options meet the criteria for testing within the FastTRK program.

The company will use the proceeds to advance several biomarker-driven targeted drugs in its pipeline, including a recently licensed MDM2 inhibitor.

The company will advance CAR T-cell therapies for solid tumors based on Unum's BOXR cell-based therapy platform and open an R&D facility in Cambridge, Mass.

The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.

In heavily pretreated adults with Hodgkin's lymphoma, the therapy resulted in mostly grade 1 adverse events and no neurologic toxicities.

The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.